Contact
searchSearch
HMP Global
Login
Videos

Jordan Berlin, MD, Provides Highlights of Hot Topics at the 2020 Virtual GDU GI Meeting

09/25/2020
Body

Transcript:

Dr Berlin highlights his favorite part of the Great Debates and Updates in GI Malignancies and gives attendees a taste of what's to come at this year's virtual meeting.

Recent News

News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology
News
Updated IMproveMF Protocol Advances Imetelstat Plus Ruxolitinib Into Phase 1b in Frontline Myelofibrosis
07/08/2026
Stephanie Holland
Results from an updated protocol presented at the ASCO Annual Meeting describe the phase 1b expansion of the IMproveMF trial, which is evaluating imetelstat plus ruxolitinib as frontline therapy for patients with intermediate- or high-risk...
Results from an updated protocol presented at the ASCO Annual Meeting describe the phase 1b expansion of the IMproveMF trial, which is evaluating imetelstat plus ruxolitinib as frontline therapy for patients with intermediate- or high-risk...
Results from an updated protocol...
07/08/2026
Oncology
News
Mirvetuximab Plus Carboplatin Remains Active Following Prior PARP Inhibitor Therapy in FRα-Positive Recurrent Platinum-Sensitive Ovarian Cancer
07/08/2026
Emily Estrada
Results from the phase 2 IMGN853-0420 trial demonstrated that mirvetuximab soravtansine plus carboplatin remained active patients with FRα-positive recurrent platinum-sensitive ovarian cancer, regardless of PARP inhibitor exposure.
Results from the phase 2 IMGN853-0420 trial demonstrated that mirvetuximab soravtansine plus carboplatin remained active patients with FRα-positive recurrent platinum-sensitive ovarian cancer, regardless of PARP inhibitor exposure.
Results from the phase 2...
07/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use